Multiple Myeloma (MM) Quality of Life (QOL) Study

Status unconfirmed

Conditions studied: Multiple Myeloma, Quality of Life, Symptom, Behavioral

In brief

The main purpose of this study is to examine differences in quality of life and psychological distress for both Multiple Myeloma patients receiving treatment and their caregivers and to assess patient and caregiver prognostic understanding (understanding of the likely course of a disease over time) of Multiple Myeloma to guide development of more personalized treatment plans. This study looks to further understand quality of life changes throughout multiple myeloma therapy for both patients and caregivers to help determine ways to improve patient and caregiver understanding of illness and in turn, tailor customized treatment that best aligns with patient preferences. The study will use a series of questionnaires to measure quality of life, mood, coping strategies, and prognostic understanding.

Key facts

Study ID

NCT04388735

Run by

Massachusetts General Hospital

People needed

360

Starts

2020-06-01

Expected to finish

2022-05-16

Last updated by the study team

2020-05-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient Eligibility criteria:
• Adult patients (greater than 18 years) receiving active therapy for MM.
• For patients with newly diagnosed MM, patients are eligible while undergoing induction therapy prior to received autologous stem cell transplant but not after.
• Ability to read questions in English or willing to complete questionnaires with the assistance of an interpreter.
• Caregiver Eligibility criteria:
• Adult (greater than 18 years) relative or a friend of a patient who agrees to participate in the study whom the patient identified as living with them or having in-person contact with him or her at least twice per week.
• Ability to read and respond to questions in English or to complete questionnaires with minimal assistance of an interpreter

You may not qualify if…

• Patient Exclusion criteria:
• Patients receiving maintenance therapy only.
• Significant psychiatric or other co-morbid disease, which the treating clinician believes prohibits informed consent or participation in the study.

Where it is running

• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.